Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in SCCOHT
NCT05368207Completed
- Sponsor
- University Health Network
- Start
- Dec 2021
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT), sponsored by University Health Network. Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2021; status: completed.
02
Drugs
03
Conditions
Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT)
Beyond the preview
Go deeper on NCT05368207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368207.